Therapies for COVID-19

Therapeutic strategies for COVID-19: progress and lessons learned

Hundreds of potential drugs for COVID-19 have been investigated in the past three years. Read about the progress and lessons learned in this article in the June issue              

  • Guangdi Li
  • Rolf Hilgenfeld
  • Erik De Clercq
Review Article



    • Substituting a hydrogen atom with its heavy isotope deuterium may improve the pharmacokinetic and/or toxicity profile of a drug compared with its non-deuterated counterpart. This article highlights milestones in the field of deuteration in drug discovery and development, and discusses recent examples of its application, which have shifted towards deuteration of novel drug candidates instead of developing deuterated analogues of marketed drugs.

      • Rita Maria Concetta Di Martino
      • Brad D. Maxwell
      • Tracey Pirali
      Review Article
    • Many diseases involve reduced or absent levels of a particular protein and would benefit from therapies that increase gene expression. In their Review, Khorkova et al. discuss the growing range of RNA-targeted therapies in development that aim to boost gene expression, including nucleic acid-based therapeutics targeting the complex regulatory network of non-coding RNA species.

      • Olga Khorkova
      • Jack Stahl
      • Claes Wahlestedt
      Review Article
    • The COVID-19 pandemic spurred a wave of rapid and collaborative drug discovery efforts. This Perspective article summarizes scientific drivers and considerations behind such antiviral small-molecule discovery programmes and proposes strategies to accelerate future efforts.

      • Annette von Delft
      • Matthew D. Hall
      • Alpha A. Lee
    • There have been significant recent advances in the development of single-cell technologies, providing remarkable opportunities for drug discovery and development. Here, Ferran and colleagues discuss how single-cell technologies, primarily single-cell RNA sequencing methods, are being applied in the drug discovery pipeline, from target identification to clinical decision-making. Ongoing challenges and potential future directions are discussed.

      • Bram Van de Sande
      • Joon Sang Lee
      • Edgardo Ferran
      Review Article
    • Since the COVID-19 pandemic began, many potential therapeutics that target SARS-CoV-2 and/or human proteins to control viral infection have been investigated, with a few receiving authorization by regulatory agencies. This Review article summarizes progress with COVID-19 drug discovery, and discusses the lessons learned about aspects such as drug repurposing, disease models and clinical development strategies.

      • Guangdi Li
      • Rolf Hilgenfeld
      • Erik De Clercq
      Review Article

Nature Careers


  • Research Group Heads, BeiGene Institute

    A cross-disciplinary research organization where cutting-edge science and technology drive the discovery of impactful Insights

    Pudong New Area, Shanghai

    BeiGene Institute

  • ADME Lead, Bio-Island

    DMPK/PD representative in multi-functional expert teams for the evaluation of new chemical entities

    Guangzhou, Guangdong, China

    BeiGene Ltd.

  • Specialist in Genetic Trials and Precision Medicine

    The position We are looking for a highly qualified and innovative Specialist in Genetics Trials and Precision Medicine, to implement cutting-edge h...

    Oxford, Oxfordshire

    Novo Nordisk

  • Associate or Full Professor

    San Antonio, Texas

    University of Texas Health San Antonio

  • Principle Investigator

    Talented individuals with a passion for algorithm development and clinical informatics, AI in health sciences, real-world data analytics, AI for dr...

    Shanghai, China

    Intelligent Medicine Institute, Fudan University